Results for tag: "Adult T Cell Leukemia Lymphoma Drug"

Adult T Cell Leukemia Lymphoma (ATLL) is a rare type of cancer that affects the T cells of the immune system. It is caused by a virus called human T-cell lymphotropic virus type 1 (HTLV-1). Treatment for ATLL is typically chemotherapy, radiation therapy, and/or stem cell transplantation. In recent years, several drugs have been developed to specifically target ATLL, including arsenic trioxide, romidepsin, and mogamulizumab. Arsenic trioxide is an FDA-approved drug for the treatment of ATLL. It works by inducing apoptosis, or programmed cell death, in the cancer cells. Romidepsin is an HDAC inhibitor that has been approved for the treatment of cutaneous T-cell lymphoma, and is being studied for its potential use in ATLL. Mogamulizumab is an anti-CCR4 monoclonal antibody that has been approved for the treatment of ATLL in Japan. The Adult T Cell Leukemia Lymphoma Drug market is a rapidly growing segment of the Leukemia Drugs market. Companies such as Celgene, Takeda, and Daiichi Sankyo are actively developing and marketing drugs for the treatment of ATLL. Other companies such as Merck, Pfizer, and Novartis are also involved in the development of ATLL drugs. Show Less Read more